Recently,Thermo Fisher Scientific announced that it plans to acquire Mesa Biotech,INC with USD 450 million in cash and a milestone payment of USD 100 million.

HOB Biotech Group (HOB) and Shanghai Liferiver Biotech Co., Ltd. were successfully listed on Shanghai Stock Exchange in January 2021.

January 18, 2021, Pfizer China and Cepheid China formally signed a strategic cooperation agreement in Shanghai.

Sansure Biotech released an announcement of performance increase on January 18, and it is expected that the net profit attributable to the owners of the parent company will be realized from 2.556 billion yuan to 2.8626 billion yuan in 2020.

In January 2021, Beijing Targeting One Biotechnology Co., Ltd. (hereinafter referred to as " Targeting One") announced the completion of 150 million round B financing.

There is a vaccine race, but not between countries. It is a race between humans to develop vaccines and novel coronavirus.

Recently, Shanghai Runda Medical Technology Co., Ltd. disclosed to the public that the company will acquire part of the shares of two IVD companies in Anhui and Shanghai at a price of 328 million.

Till this report, there are 14 Chinese IVD enterprise successfully developed the B.1.1.7 testing kits.

The State Council Information Office P.R.C.announced that the Sinopharm COVID-19 Vaccine has been approved.

2020 has been a magical year for the in vitro diagnostic industry. How will history record the year 2020?

Vazyme's IPO was Accepted, Planning to Raise 1.225 Billion Yuan; Amoy Diagnostics, Merck KGaA Partner for Lung Cancer Companion Diagnostic Development in China.

Another Capital Raising Boom in in vitro diagnostic industry.

In recent years, because of the optimistic attitude about the development of IVD industry, various VC and PE investments are very active.

On December 19, at the 16th International Respiratory Symposium in Changshu, Abbott announced that it had joined the International Smart Health Alliance and signed an important strategic cooperation with the China Lung Cancer Prevention Alliance.

On December 18, 2020, Hipro biotechnology Corp announced the completion of the c-round financing of over 100 million YUAN.